
FORT LAUDERDALE, Fla--Recently, the FDA approved recombinant interleukin-11 (rIL-11 or oprelvekin, Neumega) for the prevention of severe thrombocytopenia in cancer patients with solid tumors or lymphoma. The availability of platelet growth factors represents a significant breakthrough in oncology, and methods are needed to help incorporate these agents into clinical practice guidelines.
